Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CDCP1+ mesenchymal stem cells preferentially inhibit acute graft-versus-host disease(aGVHD)

View Full Paper
Ask AI
Bookmark
Share

Authors

LYLun Yan

Discussion

Loading...

Member takes

Overview

Analysis reveals CDCP1+ mesenchymal stem cells reduce aGVHD severity in mice, indicating potential for cell therapy.

Key Points

  • CDCP1+ mesenchymal stem cells demonstrated a stronger negative regulatory effect on T cell proliferation, inhibiting immune responses.
  • Cytokines such as TNF-α and IL-6 decreased significantly in response to CDCP1+ MSC infusion, promoting Treg differentiation.
  • Single-cell sequencing identified CDKN2B as crucial in regulating immunosuppressive T cell differentiation within aGVHD models.
  • The findings suggest CDCP1+ MSCs derived from umbilical cord may enhance therapeutic efficacy in preventing aGVHD.

Cite This Study

Lun Yan (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1a3https://doi.org/10.1182/blood-2025-2466
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mesenchymal stromal cells in the prophylaxis of graft vs host disease: A meta analysis2025
  2. 2An optimized MSC product promotes GvHD prophylaxis through exosome-mediated regulatory T cell induction2025 · 1 citations
  3. 3Mesenchymal stromal cells for the prophylaxis of graft-versus-host disease after hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials2025 · 1 citations
  4. 4Immunological mechanisms underlying the novel application of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) in graft-versus-host disease (GvHD) therapy2025 · 3 citations
  5. 5Mesenchymal stem cells for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: A multicenter, single-arm, pivotal clinical Trial2025